Tuesday, February 21, 2017 10:35:22 AM
•Nutra Pharma is in the process of introducing cobra toxin-based therapies for human and pet pain management markets and additionally has therapeutic drug development opportunities relative to HIV and MS.
•OTC sales are being driven by retail expansion and DRTV programs.
•The worldwide pain management market is of significant size and is undergoing dramatic change as physicians significantly curtail narcotic prescriptions. This is creating new opportunities for innovative pain treatment therapies and products. There is much focus on this sector.
•The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
•While we do not believe it to be the near term market opportunity for the Company, it also has a strong pipeline of possible therapies for autoimmune diseases and HIV. Orphan drug status as been granted for RPI-78M.
•In our opinion, this is an innovative company with a therapy that is exciting and could capture the imagination of risk-averse investors, yielding a significantly higher, stock price.
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM